Top Management Presentation Financial Results of Fiscal Year 2012

from the beginning

Top Management Presentation Financial Results of Fiscal Year 2012

presenter :

Joji Nakayama
President and CEO

• Overview of FY2012 Results and FY2013 Forecast

• Overview of FY2012 Results - compared with FY2011 results -(1)

• Overview of FY2012 Results - compared with FY2011 results -(2)

• Overview of FY2012 Results - compared with FY2011 results -(3)

• Principal management objectives in FY2013

• Overview of FY2013 Forecast- compared with FY2012 results -(1)

• Overview of FY2013 Forecast- compared with FY2012 results -(2)

• Sales of Olmesartan (Local Currency Basis)

• Sales of Major Products in Japan

• US and Europe Priorities and Challenges in FY2013

• Emerging countries Priorities and Challenges in FY2013

• Ranbaxy Priorities and Challenges in FY2013

Global Research & Development

presenter :

Glenn Gormley MD PhD
Global Head of R&D
Senior Executive Officer

• Index

• Prasugrel (CS-747):Anti-platelet agent

• Study Design

• Primary Efficacy Endpoint(MACE at 24 weeks)

• Non-CABG Clinically Important Bleeding Events

Edoxaban (DU-176b):Clinical Program

• Major R&D Pipeline

• Promising Projects Beyond FY2017

• Tivantinib Phase 2 data in Hepatocellular Carcinoma (HCC)-1

• Tivantinib Phase 2 data in Hepatocellular Carcinoma (HCC)-2

• Mode of Action for DS-5565

• R&D Key Milestones in FY2013

• Global Research Network

Contact address regarding this material

PartI Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7

• Q&A 8

PartII Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5